BioNTech to Acquire Biotheus to Boost Oncology Strategy
BioNTech SE (Nasdaq: BNTX, "BioNTech") and Biotheus ("Biotheus") today announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage biotechnology company dedicated to the discovery and development of novel antibodies to address unmet medical needs of patients with oncological or inflammatory diseases.
VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...
With the help of TBWA\Chiat\Day New York, pharma giant Moderna is demystifying mRNA science for the average consumer. This ...
RESEARCHERS from SINTEF have developed a “simpler” low-cost carbon capture and storage (CCS) system for sequestering ...
BioNTech is upping its bet on a PD-L1xVEGF-A bispecific, paying $800 million upfront to buy its Chinese partner Biotheus ...
Investor's Business Daily on MSN20h
BioNTech Stock Got A IBD RS Rating LiftHow Much Money To Invest Now. Is BioNTech Stock A Buy? BioNTech stock is building a consolidation with a 131.49 buy point.
BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...
Analysts have set 12-month price targets for BioNTech, revealing an average target of $132.24, a high estimate of $171.00, ...
BioNTech SE and Biotheus (Biotheus) announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage biotechnology company dedicated to the discovery and development ...
On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...
Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...
Shares of vaccine makers fell as President-elect Donald Trump nominated Robert F. Kennedy Jr., a prominent vaccine skeptic, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback